Persantine Aspirin Trial
|
Status:
Trial complete. Results published 1985.
Purpose:
To test the relative efficacies of aspirin and dipyridamole in the reduction of cerebral and retinal infarction or death in patients with a history of TIA.
Location(s):
U.S. and Canada
Design:
Double-blind, randomized, cooperative trial of 890 patients at 15 centers in the U.S. and Canada.
Inclusion Criteria
Carotid territory TIAs (monocular or hemispheric) with or without persistent minor deficit.
Exclusion Criteria
Experiencing only vertebrobasilar TIAs, other serious concurrent illness, required to take anticoagulants or other drugs that influence platelet function, carotid endarterectomy recommended, too unreliable to adhere to protocol, difficulties anticipated in return for follow-up visits, possible cardiac source for emboli, history of peptic ulcer or bleeding or clotting disorder, most recent carotid territory TIA occurred >3 months before initial evaluation.
Patient Involvement:
Patients were randomized to receive either aspirin (325 mg) plus placebo four times daily or aspirin (325 mg) plus dipyridamole (75 mg) four times daily. The decision to continue or discontinue the study medications was left to the attending physician. Follow-up visits were scheduled to take place every three months beginning one month after randomization. Median total follow-up time was 25 months.
Primary Outcome:
Stroke, retinal infarction, or death from any cause.
Secondary Outcome:
Subgroup analyses, deaths, adverse events.
Results:
There were no differences between the two treatment groups.
Source of Information:
Published report 1985.
|
|
Web Links and Publications:
|
|
This information last updated on: 4/30/2001
|
Trials
Directories